Keith Flaherty
基思·弗拉赫蒂
MD
Director, Termeer Center for Targeted Therapy; Director, Henri and Belinda Termeer Center for Targeted Therapy特米尔靶向治疗中心主任
👥Biography 个人简介
Keith Flaherty is the preeminent architect of BRAF-targeted therapy for melanoma at Massachusetts General Hospital. He led the pivotal BRIM-3 trial that established vemurafenib, discovered the clinical paradox of BRAF inhibitor-induced MAPK pathway activation, and has driven precision oncology across multiple tumor types.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BRAF Inhibitor Development
Led the pivotal BRIM-3 trial establishing vemurafenib as the first targeted therapy to improve survival in BRAF V600E-mutant melanoma, winning FDA approval and transforming treatment paradigms.
BRAF/MEK Combination Therapy
Conducted early combination BRAF and MEK inhibitor trials, identifying the mechanistic rationale and demonstrating enhanced efficacy with reduced toxicity over BRAF monotherapy.
Precision Oncology Infrastructure
Developed the NCI-MATCH precision medicine trial, applying tumor agnostic targeted therapy principles across diverse cancer types based on molecular alterations.
Representative Works 代表性著作
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (BRIM-3)
New England Journal of Medicine (2011)
Pivotal phase III trial establishing vemurafenib as the first FDA-approved targeted therapy for BRAF-mutant melanoma, improving overall survival.
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
New England Journal of Medicine (2010)
First-in-human proof-of-concept study showing dramatic tumor regression with PLX4032 (vemurafenib) in BRAF V600E-mutant melanoma.
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
New England Journal of Medicine (2012)
Demonstrated superior progression-free survival with dabrafenib plus trametinib versus vemurafenib monotherapy, establishing the combination standard.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
University of California, Los Angeles (UCLA)
Caroline Robert
Institut Gustave Roussy
Jedd Wolchok
Memorial Sloan Kettering Cancer Center / Weill Cornell Medicine
Alexander Eggermont
Princess Máxima Center / Institut Gustave Roussy
关注 基思·弗拉赫蒂 的研究动态
Follow Keith Flaherty's research updates
留下邮箱，当我们发布与 Keith Flaherty（Massachusetts General Hospital / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment